Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Double-blind Other

Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy

Cow's Milk Allergy

Enrolled (actual)
40
Serious AEs
2.6%
Results posted
Jan 2020
Primary outcome: Primary: Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula — 0; 0; 0; 30 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
New Amino Acid formula (Other); Commercially available Amino Acid Formula (Other)
Age
Pediatric
Sex
All
Sponsor
Laboratorios Ordesa
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula
0; 0; 0; 30; 30; 30
SECONDARY
Cow's Milk Allergy Related Symptoms
1.37; 0.79

Summary

This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged< 12 years with documented cow's milk protein allergy (CMPA).

Eligibility Criteria

Inclusion Criteria

  • Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2):
  • Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
  • Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
  • Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
  • Aged ≤12 years of age at screening.
  • Expected consumption of a minimum of 250ml of study formula per day during the open challenge.
  • Written informed consent from one or both parents (depending on the local legislation) or legal representative.

Exclusion Criteria

  • Children who receive breastfeeding at study enrolment.
  • Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
  • Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
  • Existing illness that could interfere with formula acceptance or identification of allergic reactions.
  • Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
  • Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02414243). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search